CytoMed Therapeutics (GDTC) H2 2025 earnings summary

Executive summary

• Clinical-stage biopharma focused on allogeneic, off-the-shelf cell-based immunotherapies for cancer and degenerative diseases, with five product candidates in development: CTM-N2D, iPSC-gdNKT, CTM-GDT, CTM-MSC, and CTM-NK.

• Lead candidate CTM-N2D is in Phase I clinical trial (ANGELICA Trial) in Singapore; other candidates are in preclinical or IND-enabling stages.

• Expanded into private blood banking services in Malaysia, leveraging acquired assets and licenses.

Financial highlights

• No revenue from approved cell therapies; revenue generated from private blood banking services and research income (cost recovery basis).

• FY2025 revenue: S$252,265 (down from S$324,387 in 2024); research income increased to S$536,461.

• Net loss for FY2025: S$4.00 million (vs. S$2.52 million in 2024); loss would be S$2.72 million excluding non-cash share-based payments and public company costs.

• Cash and bank balances at year-end 2025: S$2.10 million (down from S$4.97 million in 2024).

• Research expenses rose to S$2.22 million in 2025 (from S$1.91 million in 2024), driven by higher consumables, employee benefits, and clinical trial costs.

• Share-based compensation of S$694,200 recognized in 2025.

Outlook and guidance

• Expect continued losses as R&D and clinical activities expand; future profitability dependent on successful product development and commercialization.

• Ongoing ATM equity offering and potential additional financings to support operations; no commitments for further financing as of year-end.

• Focus on advancing clinical trials for CTM-N2D and CTM-GDT, and preclinical development for other candidates.